INTRODUCTION {#sec1-1}
============

Atherosclerotic vascular disease is the major cause of morbidity and mortality in postmenopausal women. Hormone replacement therapy (HRT), though indicated as cardio-protective,\[[@ref1]\] is associated with an increased risk of endometrial hyperplasia, carcinoma,\[[@ref2]\] breast cancer,\[[@ref3]\] and thromboembolism.\[[@ref4]\] Efforts have been made to develop agents that prevent estrogen-deficiency-related clinical disorders and are free from estrogen-related health hazards.

Selective estrogen receptor modulators (SERM), by virtue of their tissue-selective pharmacology,\[[@ref5]\] have attracted attention of researchers in recent years. Ormeloxifene is one such multifunctional nonsteroidal SERM possessing potent estrogen-antagonistic and weak estrogen-agonistic activities and has been marketed in India as once-a-week oral contraceptive.\[[@ref6]\] It prevents ovariectomy-induced bone loss\[[@ref7]\] by inhibiting generation and activity of osteoclasts.\[[@ref8]\] In women, ormeloxifene (30 mg/week) administered for 1 year does not cause hyperaggregability of platelets. Lack of effect of ormeloxifene (up to 80 mg/kg) on vascular cycloxygenase activity in rats at concentrations inhibiting malonaldehyde synthesis suggest sparing effect of ormeloxifene that might prove beneficial against risk of thrombotic episodes by shift of balance towards more beneficial antiaggregatory prostaglandin-I~2~.\[[@ref5][@ref9]\] Raloxifene, that mimics effects of estrogen in bone and cardiovascular system and exhibits estrogen-antagonistic effect on endometrium,\[[@ref10]\] increases incidence of hot flushes, deep vein thrombosis, pulmonary embolism and leg cramps in women similar to that associated with HRT use and exhibit potent estrogenic responses in animals.\[[@ref7]\] This study investigates short-term effects of ormeloxifene on systemic hemodynamics, coagulation profile, and serum antioxidant activity in comparison to raloxifene in adult female rats, no information on which is available.

MATERIALS AND METHODS {#sec1-2}
=====================

Animals {#sec2-1}
-------

Colony-bred adult (180 -200 g) virgin female Sprague-Dawley rats maintained under standard conditions with alternate 12 h light/dark periods and free access to pellet diet and tap water as per CPCSEA guidelines were used. The study protocol was approved by the Institutional Animal Ethics Committee.

Chemicals {#sec2-2}
---------

Raloxifene was purchased (Ralista-Cipla Ltd., India) and ormeloxifene (INN for centchroman\[[@ref6]\]) was synthesized\[[@ref11]\] and stored as directed. All other chemicals were of analytical grade.

Animals and treatment {#sec2-3}
---------------------

Rats were randomized into 19 groups of ten each and kept in plastic cages containing dry rice husk. Animals received either ormeloxifene or raloxifene (0.25, 1.25, or 3 mg/kg) once daily for 7, 15, or 30 days by the oral route. Animals of the control group received the vehicle (gum-acacia in distilled water) alone in a similar manner. Ormeloxifene and raloxifene were individually macerated with almost equal quantity of gum-acacia and suspended in distilled water to achieve desired concentrations such that each rat received 0.2 ml of freshly prepared suspension/100 g body weight.\[[@ref7]\] Doses used included contraceptive dose (0.25 mg/kg/day)\[[@ref12]\] of ormeloxifene and dose of ormeloxifene (1.25 mg/kg/day)\[[@ref7]\] and raloxifene (3 mg/kg/day)\[[@ref13]\] required to preserves bone mass in ovariectomized rats. Twenty-four-hours after the last treatment, trachea of each rat, maintained on a heating table (37 °C; HugoSachs Electronic, Germany), was cannulated under pentobarbital anesthesia.\[[@ref14]\] Intermittent positive pressure respiration with oxygen-atmospheric air mixture (2.5 ml, 120/min) was maintained using Animal Ventilator (Harvard Apparatus, USA).

Hemodynamics {#sec2-4}
------------

Common carotid arteries were dissected free and mean blood velocity was measured in right carotid artery with 20 MHz pulsed-Doppler flow probe (CBI-8000; Crystal Biotech, Hopkinton).\[[@ref15]\] Left carotid artery was cannulated with heparinized (50 U heparin/ml physiological saline) polyethylene cannula connected to pressure transducer for measurement of systolic and diastolic pressure using data acquisition system (Biopac Systems Inc., USA) and mean arterial blood pressure was calculated.\[[@ref16]\] Electrocardiogram was recorded using ECG-100C (NICO-100C, Biopac Systems Inc., USA). Monitoring electrodes placed subcutaneously on lower chest were connected to transducers and amplifiers. After 5 min equilibration, hemodynamic parameters were recorded for 20 min. One milliliter blood was collected from carotid artery of each rat via catheter for antioxidant activity estimation.

Coagulation parameters {#sec2-5}
----------------------

Coagulation parameters were estimated only in rats treated with 3 mg/kg/day dose of ormeloxifene or raloxifene for 30 days. Thrombin time (TT), prothrombin time (PT), and activated partial thromboplastin time (aPTT) were assessed\[[@ref17]\] in platelet poor plasma (PPP) using semi-automated coagulometer (Start4, Young Instruments, France) and STA thrombin reagent, Neoplastin CI plus, Fibri-Prest and CK Prest, respectively, according to the manufacturer\'s instructions. For PPP, blood collected by cardiac puncture using syringe containing 3.2% trisodium citrate was centrifuged at 2500 × g for 15 min at 20°C.

Antioxidant activity {#sec2-6}
--------------------

Serum total antioxidant activity (AOA) was estimated according to Koracevic *et al*.\[[@ref18]\] Uric acid (1 mmol/l in 5 mmol/l NaOH) was used as standard.

Statistical analysis {#sec2-7}
--------------------

Comparisons between different groups were made using two-way ANOVA with Newman-Keuls multiple comparison test. Microcal software version 6.0 was used for data analysis.\[[@ref19]\] A *P* value \< 0.05 was considered significant.

RESULTS {#sec1-3}
=======

Hemodynamic parameters {#sec2-8}
----------------------

Both ormeloxifene and raloxifene administered up to 3 mg/kg daily dose for up to 30 days did not significantly alter any hemodynamic parameters, viz., heart rate (vehicle control group: 337.0 ± 11.4 beats/min), mean blood velocity (vehicle control group: 17.2 ± 1.4 cm/sec), systolic, diastolic, and mean blood pressure (vehicle control group: 152.3 ± 4.7, 112.3±3.9, and 125.7 ± 3.8, respectively) in adult female rats. There was also no observable effect on different parameters of heart \[[Table 1](#T1){ref-type="table"}\], except that both ormeloxifene (3 mg/kg × 30 days) and raloxifene (3 mg/kg × 7 days) significantly (*P* \< 0.05) increased amplitude of R wave signal \[[Figure 1](#F1){ref-type="fig"}\]. In rats treated with 0.25 and 1.25 mg/kg/day doses of ormeloxifene for 30 days, the amplitude of R wave was 0.12 ± 0.01 and 0.12 ± 0.02 V, respectively, which was not significantly different from controls \[0.14 ± 0.02 V, [Table 1](#T1){ref-type="table"}\]. In rats treated with 3 mg/kg daily dose of ormeloxifene for 30 days, the amplitude of R wave (0.24 ± 0.02 V) increased by 71.4% (*P* \< 0.05) as compared to vehicle control level. In rats treated with 0.25 and 1.25 mg/kg daily doses of raloxifene for 7 days, the amplitude of R wave was 0.09 ± 0.01 and 0.09 ± 0.02 V, respectively. In comparison, in rats treated with 3 mg/kg daily dose of raloxifene for 7 days, the amplitude of R wave (0.26 ± 0.01 V) was increased by 85.7% (*P* \< 0.05). This effect of raloxifene was not manifested when duration of treatment was increased to 15 or 30 days.

###### 

Effect of ormeloxifene and raloxifene on electrocardiogram in adult female rats
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![R wave of adult female rats treated with vehicle (a, b, c), ormeloxifene (3 mg/kg/day; d, e, f), or raloxifene (3 mg/kg/day; g, h, i) for 7, 15, or 30 days, respectively. Significant (*P* \< 0.05) increase in amplitude of R wave was observed in rats treated with 3 mg/kg/day dose of ormeloxifene for 30 days, which in raloxifene treated rats was evident only 7 days after treatment at this dose](JPP-2-90-g002){#F1}

Coagulation parameters {#sec2-9}
----------------------

No significant change was observed in coagulation profile (thrombin time, prothrombin time, or activated partial thromboplastin time; mean ± SEM in seconds) of animals after administration of either drug (vehicle versus ormeloxifene - TT: 48.5±7.1 versus 49.5 ± 6.5; PT: 18.8 ± 3.2 versus 17.6 ±0.9; aPTT: 16.7±0.3 versus 16.2±0.9; vehicle versus raloxifene - TT: 32.6 ± 3.3 versus 34.3 ± 5.1; PT: 14.4 ± 0.4 versus 15.1 ± 0.3; aPTT: 17.0 ± 0.2 versus 16.8 ± 1.2) at the highest (3mg/kg/day) dose administered for the longest duration of observation (i.e., 30 days).

Antioxidant activity {#sec2-10}
--------------------

There was no significant difference in serum total AOA (mmol/l; mean ± SEM) in rats receiving ormeloxifene or raloxifene at these doses and schedules. Apparent increase in AOA in rats receiving ormeloxifene \[0.25 (1.89 ± 0.07), 1.25 (1.87 ± 0.10), or 3 (1.70 ± 0.07) mg/kg/day for 15 days) or raloxifene (1.25 mg/kg/day for 7 days; 1.69 ± 0.06) was statistically nonsignificant when compared to that in rats receiving vehicle alone for 30 days (1.39 ± 0.09).

DISCUSSION {#sec1-4}
==========

Results of this study demonstrate lack of effect of ormeloxifene administered at its contraceptive, antiresorptive and higher doses in different schedules on various hemodynamic parameters in adult female rats. There was also no observable effect on different heart parameters, except increase in amplitude of R wave in rats treated with the highest (3 mg/kg/day) dose of ormeloxifene for 30 days. This effect in case of raloxifene was evident only 7 days after treatment at this dose. While this might be related to stronger ventricular contractions after administration of these drugs, we did not observe any change in blood pressure or other hemodynamic parameters as a consequence of observed change in R wave in treated rats. Based on the available information, it is not possible to assign any physiological significance to increase in amplitude of R wave. Overall response was, however, almost similar in case of both the agents. According to a recent study,\[[@ref20]\] raloxifene (1 μM) does not increase QRS and QTc interval in isolated guinea pig heart suggesting it to be a safe SERM. Previous studies have also demonstrated lipid lowering effect of ormeloxifene in animal and clinical settings.\[[@ref5]\] In adult female rabbits, ormeloxifene (0.1, 1, 10 mg/kg) administered for 4 days caused 40%-70% inhibition in ovariectomy-induced increase in serum total cholesterol, without adverse effects of estrogen therapy. No increase in serum total or HDL cholesterol or triglycerides was observed in women in 30 mg/week dose phase-III multicentric trial of ormeloxifene with use duration of 1-2 years, or in lactating mothers (*n* = 4).\[[@ref5]\]

It is now well established that the relative risk of symptomatic venous thromboembolism (VTE) in healthy women associated with raloxifene use increases by 2-3-fold. Such risk translates into estimated absolute risk of 2-3 cases/1000/year,\[[@ref21]\] which is similar to the absolute risk of VTE in women using HRT.\[[@ref22]\] Slight reduction in antithrombin-III is reported after 3-6 months of raloxifene use.\[[@ref23]\] In follow-up study for 8 years involving 4011 females who were treated with raloxifene for postmenopausal osteoporosis, 1.7-fold increase in risk of VTE was observed.\[[@ref24]\] Extrapolation of available literature might suggest caution against indiscriminate use of raloxifene in women with past history of idiopathic VTE and in asymptomatic carriers of inherited hypercoagulable states.\[[@ref25]\] We did not find any significant difference in coagulation profile in rats treated with ormeloxifene or raloxifene for 30 days. This finding, however, by no means precludes that these drugs are free from coagulation side effects.

In conclusion, the findings demonstrate comparable pharmacological profile of ormeloxifene and raloxifene in a short-term administration to rats. Based on changes observed in the ECG (R wave), long-term studies may lead to justifiable comparison of beneficial and harmful effects of ormeloxifene and raloxifene in relation to cardiovascular effects.
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